<DOC>
	<DOC>NCT02730312</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.</brief_summary>
	<brief_title>PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Diagnosis of 1 of the following diseases: Primary or secondary AML (including erythroleukemia and eosinophilic leukemia, but excluding acute promyelocytic leukemia) Bcell ALL BPDCN CML in blast phase, resistant or intolerant to tyrosine kinase inhibitor therapy Patients with relapsed or refractory disease with no available standard therapy ECOG performance status 02 Not a candidate for, or refusing treatment with hematopoietic stem cell transplantation Cytotoxic chemotherapy, radiotherapy, immunotherapy or investigational agent treatment within 2 weeks of first dose of study drug Prior therapy with CD123 or IL3Rdirected immunotherapies, including monospecific and bsAbs, immunoconjugates, or chimeric antigen receptormodified Tcell therapy Failure to recover from Grade 3 or 4 toxicity from previous treatment (unrelated to malignant bone marrow involvement) Known uncontrolled central nervous system involvement by malignant disease White blood cell (WBC) count â‰¥10,000/mm3 or symptoms of leukostasis Diagnosis of promyelocytic leukemia Aspartate aminotransferase or alanine aminotransferase at screening &gt;3.0 x upper limit of normal (ULN) unless considered due to leukemic organ involvement Bilirubin &gt;1.5 x ULN, unless prior diagnosis and documentation of leukemic organ involvement, ongoing hemolysis, or Gilbert's syndrome Serum creatinine &gt;2.0 x ULN, or estimated creatinine clearance &lt;40mL/min History or evidence of a clinically unstable/uncontrollable disorder, condition or disease other than primary malignancy, that in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation Evidence of any active, uncontrolled bacterial, viral, parasitic fungal infections within 1 week of first dose of study drug Positive test for human immunodeficiency virus (HIV) I or II antibodies, hepatitis B surface antigen or core antibody, or hepatitis C virus antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>B-ALL</keyword>
	<keyword>BPDCN</keyword>
	<keyword>CML</keyword>
	<keyword>Blast Crisis</keyword>
</DOC>